Patients | Controls | |||
---|---|---|---|---|
Total | VMP | VMPT | ||
n | 124 | 53 | 71 | 54 |
Age | 71 (56–85) | 71 (60–85) | 71 (56–85) | 69 (54–88) |
Sex (M/F) | 58/66 | 24/29 | 34/37 | 24/30 |
Type of MM | NA | |||
IgG (%) | 71 (57.2) | 31 (58.5) | 46 (64.8) | |
IgA (%) | 28 (22.6) | 12 (22.6) | 14 (19.8) | |
BJ (%) | 25 (20.2) | 10 (18.9) | 11 (15.4) | |
Stage (D&S) | NA | |||
IIA (%) | 14 (11.3) | 5 (9.4) | 9 (12.7) | |
IIIA (%) | 102 (82.3) | 45 (84.9) | 57 (80.3) | |
IIIB (%) | 8 (6.4) | 3 (5.7) | 5 (7) | |
ISS stage | NA | |||
1 | 26 | 8 | 18 | |
2 | 42 | 21 | 21 | |
3 | 21 | 6 | 15 | |
Missing data | 35 | 18 | 17 | |
Cytogenetics | NA | |||
High risk | 28 | 11 | 17 | |
Standard risk | 36 | 16 | 20 | |
Missing data | 60 | 26 | 34 | |
Response | ||||
CR (%) | 47 (37.9) | 14 (26.4) | 33 (46.6) | |
VGPR (%) | 27 (21.8) | 11 (20.8) | 16 (22.6) | NA |
PR (%) | 38 (30.6) | 19 (35.8) | 19 (26.8) | |
SD (%) | 12 (9.7) | 9 (17) | 3 (4.2) | |
Relapse (Y/N) | 80/44 | 39/14 | 41/30 | NA |
Death (Y/N) | 54/70 | 22/31 | 32/39 | NA |